Emerging Therapies in Antineutrophil Cytoplasm Antibody-Associated Vasculitis

Shunsuke Furuta; David Jayne


Curr Opin Rheumatol. 2014;26(1):1-6. 

In This Article


In the field of AAV, various new drugs and potential candidates are approved or under evaluation in both clinical and experimental stages. To find optimal use of these drugs and to resolve the unmet needs, such as relapse prevention and reducing glucocorticoid dose, will be needed.